Literature DB >> 22695458

Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008.

Mary G George1, Xin Tong, Nancy Sonnenfeld, Yuling Hong.   

Abstract

Cardiovascular disease (CVD) is the most highly prevalent disease in the United States and remains the leading cause of death among adults aged ≥18 years despite advancements in treatment and prevention in recent decades. Each year, approximately 800,000 persons die from CVD, which includes coronary heart disease (CHD); the majority of those persons who die from CVD had underlying atherosclerosis. Approximately 7.9 million U.S. adults have a history of heart attack, approximately 7 million U.S. adults have a history of stroke, and, approximately 16 million U.S. adults have received a diagnosis of CHD. CVD and CHD cause a substantial economic burden in the United States. In 2010, the estimated annual cost (direct and indirect) of CVD in the United States was approximately $450 billion, including $109 billion for CHD and $54 billion for stroke alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695458

Source DB:  PubMed          Journal:  MMWR Suppl        ISSN: 2380-8942


  10 in total

1.  Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012).

Authors:  Jing Fang; Mary G George; Renee M Gindi; Yuling Hong; Quanhe Yang; Carma Ayala; Brian W Ward; Fleetwood Loustalot
Journal:  Am J Cardiol       Date:  2015-01-14       Impact factor: 2.778

2.  Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?

Authors:  Kevin Fiscella; Paul C Winters; Michael Mendoza; Gary J Noronha; Carlos M Swanger; John D Bisognano; Robert J Fortuna
Journal:  J Gen Intern Med       Date:  2015-02       Impact factor: 5.128

3.  HIV testing practices among women living in public housing in Puerto Rico.

Authors:  Lisa R Norman; Silkha Abreu; Erika Candelaria; Ana Sala
Journal:  J Womens Health (Larchmt)       Date:  2008-05       Impact factor: 2.681

4.  Increasing Receipt of Women's Preventive Services.

Authors:  Haley Stolp; Jared Fox
Journal:  J Womens Health (Larchmt)       Date:  2015-10-08       Impact factor: 2.681

Review 5.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

Review 6.  Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.

Authors:  Mohammed Jarrar; Shalini Behl; Ganiraju Manyam; Hany Ganah; Mohammed Nazir; Reem Nasab; Khaled Moustafa
Journal:  Mol Biol Rep       Date:  2016-04-12       Impact factor: 2.316

7.  Preventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 40 Years: Data from the National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Qiuping Gu; Charles F Dillon; Mark S Eberhardt; Jacqueline D Wright; Vicki L Burt
Journal:  Public Health Rep       Date:  2015 Nov-Dec       Impact factor: 2.792

8.  Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.

Authors:  Arch G Mainous; Rebecca J Tanner; Ronald I Shorr; Marian C Limacher
Journal:  J Am Heart Assoc       Date:  2014-07-14       Impact factor: 5.501

Review 9.  Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment.

Authors:  Byron Cryer; Kenneth W Mahaffey
Journal:  J Multidiscip Healthc       Date:  2014-03-03

10.  Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.

Authors:  Samuel Tchwenko; Eleanor Fleming; Geraldine S Perry
Journal:  Prev Chronic Dis       Date:  2015-11-19       Impact factor: 2.830

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.